000186458 001__ 186458
000186458 005__ 20240918080736.0
000186458 0247_ $$2doi$$a10.3390/pharmaceutics14122688
000186458 0247_ $$2pmid$$apmid:36559182
000186458 0247_ $$2pmc$$apmc:PMC9781439
000186458 0247_ $$2altmetric$$aaltmetric:148385787
000186458 037__ $$aDKFZ-2022-03179
000186458 041__ $$aEnglish
000186458 082__ $$a610
000186458 1001_ $$aTrochopoulos, Antonios G X$$b0
000186458 245__ $$aMicellar Curcumin Substantially Increases the Antineoplastic Activity of the Alkylphosphocholine Erufosine against TWIST1 Positive Cutaneous T Cell Lymphoma Cell Lines.
000186458 260__ $$aBasel$$bMDPI$$c2022
000186458 3367_ $$2DRIVER$$aarticle
000186458 3367_ $$2DataCite$$aOutput Types/Journal article
000186458 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726639628_14745
000186458 3367_ $$2BibTeX$$aARTICLE
000186458 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186458 3367_ $$00$$2EndNote$$aJournal Article
000186458 520__ $$aCutaneous T-cell lymphoma (CTCL) is a rare form of cancer with local as well as systemic manifestations. Concomitant bacterial infections increase morbidity and mortality rates due to impaired skin barrier and immune deficiency. In the current study, we demonstrated that the in vitro anti-lymphoma potential of erufosine is diminished by TWIST1 expression and micellar curcumin substantially increases its antineoplastic activity. Pharmacokinetic analysis showed that the micellar curcumin (MCRM) used in our study was characterized by low zeta potential, slow release of curcumin, and fast cell membrane penetration. The combination ratio 1:4 [erufosine:MCRM] achieved strong synergism by inhibiting cell proliferation and clonogenicity. The combined antiproliferative effects were calculated using the symbolic mathematical software MAPLE 15. The synergistic combination strongly decreased the expression of TWIST1 and protein kinase B/Akt as proven by western blotting. Significant reductions in NF-κB activation, induction of apoptosis, and altered glutathione levels were demonstrated by corresponding assays. In addition, the synergistic combination enhanced the anti-staphylococcal activity and prevented biofilm formation, as shown by crystal violet staining. Taken together, the above results show that the development of nanotechnological treatment modalities for CTCL, based on rational drug combinations exhibiting parallel antineoplastic and antibacterial effects, may prove efficacious.
000186458 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000186458 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186458 650_7 $$2Other$$aTWIST1
000186458 650_7 $$2Other$$acurcumin
000186458 650_7 $$2Other$$acutaneous T-cell lymphoma
000186458 650_7 $$2Other$$aerufosine
000186458 650_7 $$2Other$$ananotechnology
000186458 650_7 $$2Other$$asynergy
000186458 7001_ $$00000-0001-7784-4488$$aIlieva, Yana$$b1
000186458 7001_ $$aKroumov, Alexander D$$b2
000186458 7001_ $$00000-0002-2577-5625$$aDimitrova, Lyudmila L$$b3
000186458 7001_ $$00000-0002-8974-1694$$aPencheva-El Tibi, Ivanka$$b4
000186458 7001_ $$aPhilipov, Stanislav$$b5
000186458 7001_ $$0P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aBerger, Martin$$b6
000186458 7001_ $$aNajdenski, Hristo M$$b7
000186458 7001_ $$00000-0003-2704-3054$$aYoncheva, Krassimira$$b8
000186458 7001_ $$aKonstantinov, Spiro M$$b9
000186458 7001_ $$00000-0001-8548-5649$$aZaharieva, Maya M$$b10
000186458 773__ $$0PERI:(DE-600)2527217-2$$a10.3390/pharmaceutics14122688$$gVol. 14, no. 12, p. 2688 -$$n12$$p2688$$tPharmaceutics$$v14$$x1999-4923$$y2022
000186458 909CO $$ooai:inrepo02.dkfz.de:186458$$pVDB
000186458 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000186458 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000186458 9141_ $$y2022
000186458 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICS : 2021$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-08-24T11:04:26Z
000186458 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-08-24T11:04:26Z
000186458 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-08-24T11:04:26Z
000186458 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-08-24T11:04:26Z
000186458 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bPHARMACEUTICS : 2021$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-25
000186458 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-25
000186458 9201_ $$0I:(DE-He78)G401-20160331$$kG401$$lMolekulare Toxikologie und Chemotherapie$$x0
000186458 980__ $$ajournal
000186458 980__ $$aVDB
000186458 980__ $$aI:(DE-He78)G401-20160331
000186458 980__ $$aUNRESTRICTED